Last updated: August 13, 2025
Introduction
European patent EP1968539, granted to Ablynx NV (subsequently part of Sanofi), pertains to a broad claim set encompassing nanobody-based pharmaceutical inventions. This patent holds significance within the biopharmaceutical industry, particularly in the realm of therapeutics based on single-domain antibodies. This analysis dissects its scope, claims, and the overarching patent landscape, examining strategic positioning, patent breadth, potential vulnerabilities, and competitive implications.
Overview of EP1968539
Filing and Grant Timeline
Filed as an international patent application under the Patent Cooperation Treaty (PCT) in 2008, EP1968539 entered national phases across multiple jurisdictions. The European patent was granted in 2013, claiming priority from earlier filings. It covers methods of producing, isolating, and using nanobodies—single-domain antibodies derived from camelids—for therapeutic and diagnostic purposes.
Patent Assignee
Originally assigned to Ablynx NV, a biotech company specializing in nanobody technology, which was acquired by Sanofi in 2018. The patent remains a critical asset within Sanofi’s biologics portfolio.
Scope and Claims Analysis
1. Overview of Patent Claims
EP1968539 includes multiple claims—primarily independent and dependent—covering:
- Nanobody molecules: Specific amino acid sequences, their derivatives, and variants.
- Methodologies: Techniques to produce, isolate, and characterize nanobodies.
- Applications: Therapeutic uses, including binding to specific targets, formulations, and administration routes.
- Vaccine and diagnostic uses: Diagnostic assays and vaccine formulations featuring nanobodies.
2. Core Claims and Their Breadth
The core claims focus on nanobodies binding to specific antigens, particularly targeting VHH (variable domain of heavy-chain-only antibodies) sequences. Notable features include:
-
Sequence Features: Claims encompass nanobodies with particular complementarity-determining regions (CDRs), with some claims covering amino acid sequence motifs and others broader, including variants with minor sequence modifications.
-
Target Specificity: Claims describing nanobodies binding to T-cell receptor, vascular endothelial growth factor (VEGF), or epidermal growth factor receptor (EGFR), representing prominent therapeutic targets.
-
Production Methods: Claims extend to methods of generating nanobodies through immunization, phage-display, or other recombinant techniques, including host cell systems.
-
Therapeutic & Diagnostic Use: Claims relate to delivering nanobodies for diseases such as cancer, inflammatory conditions, and infectious diseases, with some covering particular dosing or delivery regimes.
3. Claim Interpretation and Scope
The scope of EP1968539 is notably broad, especially regarding the nanobody sequences and their functional variants. The claims encompass:
-
Sequence-variant claims: Covering nanobodies with high sequence homology, often defined by sequence identity thresholds (e.g., >80%, >90%).
-
Functional claims: Covering nanobodies based on binding affinity or activity, not solely sequence.
-
Method claims: Encompassing the generation of nanobodies using recombinant techniques, hybridomas, or in vitro display methods.
This breadth provides a strategic advantage, allowing Sanofi to cover multiple nanobody embodiments, yet raises questions on potential vulnerability to challenges such as obviousness or lack of novelty if intermediate prior art emerges.
Patent Landscape Context
1. Nanobody Patent Ecosystem
The patent landscape surrounding nanobodies includes numerous key patents:
-
Original Nanobody Technology: Patent families filed by Ablynx/Nanobodies NV, covering fundamental sequences, methods, and applications ([1], [2]).
-
Therapeutic Specificity: Subsequent patents focus on specific nanobody-target combinations, such as anti-TNF, anti-VEGF, or anti-RANKL, representing therapeutic commercialization efforts.
-
Complementary and Improvement Patents: Patents filing improvements in stability, delivery, bispecific constructs, and formulations.
2. Competitor Patent Activity
Major pharmaceutical firms like Ablynx, Dyax (now part of Amgen), and other biotech firms possess patents aligned with nanobodies and their uses:
-
Ablynx/Nanobodies core patents (e.g., WO2006020648) laid foundational broad claims.
-
Sanofi's patent filings have expanded on these, including EP1968539 and subsequent patents, for specific nanobodies targeting disease markers.
-
Other entities develop monoclonal antibody alternatives, with some targeting similar indications, leading to overlapping patent claims and potential litigations.
3. Patentability and Freedom-to-Operate (FTO) Considerations
While EP1968539 enjoys robust claim coverage, ongoing patent filings by competitors and prior art references challenge the validity and scope. The key considerations include:
-
Novelty: The claim set’s reliance on specific sequences or methods may be vulnerable if similar nanobodies exist.
-
Inventive Step: The broad claims on nanobodies with homology thresholds are susceptible to obviousness challenges, especially if prior art demonstrates similar sequences.
-
Litigation and Patent Thickets: The densely populated nanobody patent landscape favors strategic licensing or cross-licensing strategies.
Strategic Implications for Stakeholders
For Patent Holders (Sanofi & Ablynx)
-
Leverage Broad Claims: Use patent claims for protection against generic or biosimilar competition, especially for key therapeutic targets.
-
Monitor Clarity & Validity: Maintain rigorous patent prosecution to uphold claims amid emerging prior art.
-
Extend Patent Portfolio: File continuation and divisional applications to cover evolving nanobody innovations, including bispecifics, conjugates, and delivery systems.
For Competitors
-
Design Around Claims: Develop nanobodies with sequences outside the claimed homology thresholds or targeting alternative epitopes to avoid infringement.
-
File Blocking Patents: Secure alternative nanobody sequences or production methods to establish patent fences.
-
Challenge Validity: Use prior art to contest the validity of broad claims, especially sequence-based ones.
Conclusion and Key Takeaways
-
EP1968539 commands a strategic breadth, covering nanobody molecules, production methods, and therapeutic applications. Its scope aligns with Sanofi’s overarching nanobody platform, providing significant protection for their pipeline.
-
Claims are primarily sequence-based, with functional and application claims extending coverage, but face challenges regarding patentability in light of prior art.
-
The patent landscape for nanobodies is densely populated with overlapping patents and ongoing filings, underscoring the importance of vigilant patent prosecution and licensing strategies.
-
Stakeholders must carefully interpret claim scope, monitor patent validity, and design innovative nanobody variants outside granted claims to sustain competitive advantage.
-
Future developments will likely depend on further patent filings that narrow or expand the scope, and on legal challenges testing the validity and infringement boundaries of EP1968539.
Key Takeaways
-
Strategic intellectual property positioning is vital for nanobody-based therapeutics, with EP1968539 serving as a cornerstone patent within Sanofi’s portfolio.
-
Broad claims provide valuable coverage but could be susceptible to validity challenges, emphasizing the need for ongoing innovation and patent prosecution.
-
The dense nanobody patent landscape necessitates careful freedom-to-operate analyses and proactive patent management.
-
Emerging competitors and third-party innovators continue to file patents to carve out space in the nanobody domain, warming the landscape for potential litigation and cross-licensing.
-
Navigating this landscape requires continuous landscape analysis, emphasizing the importance for patent professionals and strategic decision-makers within biotech firms.
References
- [1] WO2006020648A1 — "VHH nanobodies". Ablynx NV, 2006.
- [2] EP2135788A1 — "Nanobodies and their use", Ablynx NV, 2008.
